• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Rockwell Medical Technologies, Inc. Signs Concentrate Supply Agreement With Fletcher Allen Health Care Renal Services

Posted on: Tuesday, 11 October 2005, 09:01 CDT

WIXOM, Mich., Oct. 11 /PRNewswire-FirstCall/ -- Rockwell Medical Technologies, Inc. , a leading, innovative dialysis products manufacturer serving the healthcare industry, reported today that it has signed a concentrate supply agreement with Fletcher Allen Health Care Renal Services.

The exclusive supply agreement calls for Fletcher Allen to purchase Rockwell's RenalPure(R) Liquid Acid Concentrate and SteriLyte(R) Liquid Bicarbonate, as well as its dialyzer reuse solution needed for cleaning artificial kidneys. The contract is for a term of two years, after which it may be extended annually upon mutual agreement of both parties. Rockwell will deliver product in bulk to distributor McKesson Medical-Surgical Maine, Inc., located in the Northeast United States. McKesson Medical is also under contract with Rockwell to deliver product directly to Fletcher Allen. Rockwell anticipates that the Fletcher Allen Supply Agreement will generate sales revenue in excess of $500,000 annually.

Fletcher Allen Health Care Renal Services provides hemodialysis and peritoneal dialysis therapy for patients with end-stage renal disease in six dialysis centers in Vermont and upstate New York.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, "We are pleased to be able to provide our concentrate and dialyzer reuse products to Fletcher Allen. The structure of this supply agreement enables us to increase our sales and expand our presence in the Northeast with a very cost effective method."

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased approximately 6%-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate(R) Dry Acid Concentrate Mixing System, RenalPure(R) Liquid Acid Concentrate, SteriLyte(R) Liquid Bicarbonate Concentrate, RenalPure(R) Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items. Visit Rockwell's website at http://www.rockwellmed.com/ for more information.

Certain statements in this press release with respect to Rockwell's anticipated sales revenue constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

Rockwell Medical Technologies, Inc.

CONTACT: Thomas Klema of Rockwell Medical Technologies, Inc.,+1-248-960-9009

Web site: http://rockwellmed.com/

Source: PRNewswire-FirstCall

More News in this Category